
Melissa Gilbert-Ross, PhD, with graduate student, Briana Brown and research specialist, Chang-Soo Seung, PhD.
Twelve Winship investigators are the newest recipients of pilot grants through Winship Invest$, a peer-reviewed program designed to fund novel, innovative cancer research projects at Winship. Winship Invest$ is supported by philanthropic contributions as well as developmental funds from Winship's Cancer Center Support Grant (P30CA138292) awarded by the National Cancer Institute of the National Institutes of Health.
Winship investigators who received funding in the current Winship Invest$ grant cycle are:
- Jin-Tang Dong, PhD
Professor, Hematology and Medical Oncology
Effects of ZFHX3 and its crosstalk with the progesterone signaling on the development and progression of breast cancer - Melissa Gilbert-Ross, PhD
Assistant Professor, Hematology and Medical Oncology
Characterization of the role of FAK in de novo resistance to immune checkpoint therapies in genetic subsets of KRAS mutant lung adenocarcinoma - Peng Jin, PhD
Professor, Human Genetics
5-hydroxymethylcytosine Alterations in Medulloblastoma - Sumin Kang, PhD
Assistant Professor, Hematology and Medical Oncology
Pro-invasive signaling of LDHA in breast cancer metastasis - Jean Koff, MD
Instructor, Hematology and Medical Oncology
Examination of B cell repertoire in patients with autoimmune disease and diffuse large B cell lymphoma - Xiaoxian "Bill" Li, MD, PhD
Assistant Professor, Pathology & Laboratory Medicine
Develop a biomarker to predict recurrence of ductal carcinoma in situ of the breast - Lauren McCullough, PhD, MSPH
Assistant Professor, Epidemiology
Obesity and breast tumor methylation in African American Women - Christopher Porter, MD
Associate Professor, Pediatrics
The function of ETV6 in B lymphopoiesis - Nabil Saba, MD, FACP
Professor, Hematology and Medical Oncology
Rafi Ahmed, PhD
Professor, Microbiology and Immunology
Georgia Chen, PhD
Professor, Hematology and Medical Oncology
Identification of Biomarkers of Response and Mechanisms of Resistance to Immunotherapy in Squamous Cell Carcinoma of the Head and Neck Cancer - Shi-Yong Sun, PhD
Professor, Hematology and Medical Oncology
Overcoming acquired resistance due to EGFR C797S mutation to 3rd generation EGFR inhibitors